- Home
- ADX vs MRUS Comparison
ADX vs MRUS Comparison
Compare ADX & MRUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADX
- MRUS
- Stock Information
- Founded
- ADX 1840
- MRUS 2003
- Country
- ADX United States
- MRUS Netherlands
- Employees
- ADX N/A
- MRUS N/A
- Industry
- ADX Investment Managers
- MRUS Biotechnology: Pharmaceutical Preparations
- Sector
- ADX Finance
- MRUS Health Care
- Exchange
- ADX Nasdaq
- MRUS Nasdaq
- Market Cap
- ADX 2.3B
- MRUS 2.7B
- IPO Year
- ADX N/A
- MRUS 2016
- Fundamental
- Price
- ADX $19.26
- MRUS $40.90
- Analyst Decision
- ADX
- MRUS Strong Buy
- Analyst Count
- ADX 0
- MRUS 14
- Target Price
- ADX N/A
- MRUS $87.00
- AVG Volume (30 Days)
- ADX 182.4K
- MRUS 770.0K
- Earning Date
- ADX 01-01-0001
- MRUS 05-07-2025
- Dividend Yield
- ADX 6.68%
- MRUS N/A
- EPS Growth
- ADX N/A
- MRUS N/A
- EPS
- ADX N/A
- MRUS N/A
- Revenue
- ADX N/A
- MRUS $54,732,000.00
- Revenue This Year
- ADX N/A
- MRUS $26.81
- Revenue Next Year
- ADX N/A
- MRUS $23.85
- P/E Ratio
- ADX N/A
- MRUS N/A
- Revenue Growth
- ADX N/A
- MRUS 42.77
- 52 Week Low
- ADX $14.94
- MRUS $33.19
- 52 Week High
- ADX $19.57
- MRUS $61.61
- Technical
- Relative Strength Index (RSI)
- ADX 56.19
- MRUS 45.06
- Support Level
- ADX $19.00
- MRUS $37.92
- Resistance Level
- ADX $19.44
- MRUS $46.36
- Average True Range (ATR)
- ADX 0.28
- MRUS 2.58
- MACD
- ADX 0.10
- MRUS -0.27
- Stochastic Oscillator
- ADX 86.08
- MRUS 35.31
About ADX Adams Diversified Equity Fund Inc.
Adams Diversified Equity Fund Inc is a diversified investment company. It is an internally-managed closed-end fund. The investment objectives of the company are the preservation of capital, the attainment of reasonable income from investments, and an opportunity for capital appreciation. It has a diversified equity portfolio which consists of securities of companies from Energy, Consumer Staples, Information Technology, Financials and other sectors.
About MRUS Merus N.V.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.